Traws Pharma reports positive first quarter 2025 results with progress on oral antiviral programs
From GlobeNewswire: 2025-05-15 07:00:00
Traws Pharma submitted FDA briefing documents on April 24, 2025, for discussions on accelerating approval for tivoxavir marboxil (TXM) and ratutrelvir for COVID, including Long COVID. The company has cash to support operations into Q1 2026. Recent financial results show revenue of $57,000 for the quarter ended March 31, 2025, with expenses related to research and development and general administration.
Traws Pharma is making progress with its oral antiviral programs for bird flu/seasonal flu and COVID. Key updates include briefing materials submitted to the FDA, preclinical study results, and Phase 1 data for both TXM and ratutrelvir. TXM is a single-dose treatment for bird flu/seasonal flu, while ratutrelvir is an oral Mpro inhibitor for COVID. The company is seeking partnerships for legacy oncology assets.
Management updates include Iain D. Dukes as the Interim CEO and Jack Stover as the Chairman of the Board. Financially, Traws had cash, cash equivalents, and short-term investments of $15.9 million as of March 31, 2025. Revenue was $57,000 for the quarter, with increased research and development expenses. Net income for the quarter was $21.5 million, driven by a change in fair value of warrant liability.
Tivoxavir marboxil (TXM) is an investigational oral endonuclease inhibitor for bird flu and seasonal flu, with positive preclinical data. Ratutrelvir is an Mpro inhibitor for COVID, showing potent activity in preclinical studies and Phase 1 data. Traws is dedicated to developing novel antiviral agents to target respiratory viral diseases.
Forward-looking statements from Traws discuss potential opportunities, risks, and uncertainties related to the development of their antiviral programs. The company continues to focus on advancing oral small molecule antivirals for bird flu/seasonal flu and COVID. For more information, visit www.trawspharma.com.
Read more at GlobeNewswire:: Traws Pharma Reports First Quarter 2025 Results and